Malmgren JA, Mayer M, Atwood MK et al (2018) Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010. Breast Cancer Res Treat 167(2):579–590

Article  PubMed  Google Scholar 

Pan H, Gray R, Braybrooke J et al (2017) 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377(19):1836–1846

Article  PubMed  PubMed Central  Google Scholar 

Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, Dent R, Fenlon D, Gligorov J, Hurvitz SA, Im SA, Krug D, Kunz WG, Loi S, Penault-Llorca F, Ricke J, Robson M, Rugo HS, Saura C, Schmid P, Singer CF, Spanic T, Tolaney SM, Turner NC, Curigliano G, Loibl S, Paluch-Shimon S, Harbeck N, ESMO Guidelines Committee (2021) ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 32(12):1475–1495. https://doi.org/10.1016/j.annonc.2021.09.019

Article  CAS  PubMed  Google Scholar 

Turner NC, Ro J, André F et al (2015) Palbociclib in hormone-receptor- positive advanced breast cancer. N Engl J Med 373(3):209–219

Article  CAS  PubMed  Google Scholar 

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, Campone M, Petrakova K, Winer EP, Janni W, Conte P, Cameron DA, André F, Arteaga CL, Zarate JP, Chakravartty A, Taran T, Le Gac F, Serra P, O’Shaughnessy J (2022) Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med 386(10):942–950. https://doi.org/10.1056/NEJMoa2114663

Article  CAS  PubMed  Google Scholar 

Goetz MP, Toi M, Campone M et al (2017) MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 35(32):3638–3646

Article  CAS  PubMed  Google Scholar 

Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F et al (2020) 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 31(12):1623–1649. https://doi.org/10.1016/j.annonc.2020.09.010

Article  CAS  PubMed  Google Scholar 

Hanker AB, Sudhan DR, Arteaga CL (2020) Overcoming endocrine resistance in breast cancer. Cancer Cell 37(4):496–513. https://doi.org/10.1016/j.ccell.2020.03.009

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garcia-Martinez L, Zhang Y, Nakata Y, Chan HL, Morey L (2021) Epigenetic mechanisms in breast cancer therapy and resistance. Nat Commun 12(1):1786. https://doi.org/10.1038/s41467-021-22024-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520–529. https://doi.org/10.1056/NEJMoa1109653

Article  CAS  PubMed  Google Scholar 

Kornblum N, Zhao F, Manola J, Klein P, Ramaswamy B, Brufsky A et al (2018) Randomized phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy: results of PrE0102. J Clin Oncol 36(16):1556–1563. https://doi.org/10.1200/JCO.2017.76.9331

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmid P, Zaiss M, Harper-Wynne C, Ferreira M, Dubey S, Chan S et al (2019) Fulvestrant plus vistusertib vs fulvestrant plus everolimus vs fulvestrant alone for women with hormone receptor-positive metastatic breast cancer: the MANTA phase 2 randomized clinical trial. JAMA Oncol 5(11):1556–1564. https://doi.org/10.1001/jamaoncol.2019.2526

Article  PubMed  PubMed Central  Google Scholar 

Lindeman GJ, Fernando TM, Bowen R, Jerzak KJ, Song X, Decker T et al (2022) VERONICA: randomized phase II study of fulvestrant and venetoclax in ER-positive metastatic breast cancer post-CDK4/6 inhibitors—efficacy, safety, and biomarker results. Clin Cancer Res 28(15):3256–3267. https://doi.org/10.1158/1078-0432.CCR-21-3811

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kalinsky K, Accordino MK, Chiuzan C, Mundi PS, Sakach E, Sathe C et al (2023) Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN Trial. J Clin Oncol 41(24):4004–4013. https://doi.org/10.1200/JCO.22.02392

Article  CAS  PubMed  Google Scholar 

Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F et al (2022) Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol 40(28):3246–3256. https://doi.org/10.1200/JCO.22.00338

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oliveira M, Pominchuk D, Nowecki Z, Hamilton E, Kulyaba Y, Andabekov T et al (2023) GS3-02 camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: results of the randomized, multi-dose phase 2 SERENA-2 trial. Cancer Res 83(5):GS3-02. https://doi.org/10.1158/1538-7445.SABCS22-GS3-02

Article  Google Scholar 

Dhakal A, Antony Thomas R, Levine EG et al (2020) Outcome of everolimus- based therapy in hormone-receptor-positive metastatic breast cancer patients after progression on palbociclib. Breast Cancer (Auckl) 14:1178223420944864

PubMed  Google Scholar 

Mo H, Renna CE, Moore HCF, Abraham J, Kruse ML, Montero AJ, LeGrand SB, Wang L, Budd GT (2022) Real-world outcomes of everolimus and exemestane for the treatment of metastatic hormone receptor-positive breast cancer in patients previously treated With CDK4/6 inhibitors. Clin Breast Cancer 22(2):143–148. https://doi.org/10.1016/j.clbc.2021.10.002

Article  CAS  PubMed  Google Scholar 

Cook MM, Al Rabadi L, Kaempf AJ, Saraceni MM, Savin MA, Mitri ZI (2021) Everolimus plus exemestane treatment in patients with metastatic hormone receptor-positive breast cancer previously treated with CDK4/6 inhibitor therapy. Oncologist 26(2):101–106. https://doi.org/10.1002/onco.13609

Article  CAS  PubMed  Google Scholar 

Karacin C, Oksuzoglu B, Demirci A, Keskinkılıç M, Baytemür NK, Yılmaz F et al (2023) Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy. BMC Cancer 23(1):136. https://doi.org/10.1186/s12885-023-10609-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rozenblit M, Mun S, Soulos P, Adelson K, Pusztai L, Mougalian S (2021) Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy. Breast Cancer Res 23(1):14. https://doi.org/10.1186/s13058-021-01394-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS, CAPItello-291 Study Group (2023) Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med 388(22):2058–2070. https://doi.org/10.1056/NEJMoa2214131

Article  CAS  PubMed  Google Scholar 

Mittal A, Molto Valiente C, Tamimi F, Schlam I, Sammons S, Tolaney SM, Tarantino P (2023) Filling the gap after CDK4/6 inhibitors: novel endocrine and biologic treatment options for metastatic hormone receptor positive breast cancer. Cancers (Basel) 15(7):2015. https://doi.org/10.3390/cancers15072015

Article  CAS  PubMed  Google Scholar 

André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Pápai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D, SOLAR-1 Study Group (2019) Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 380(20):1929–1940. https://doi.org/10.1056/NEJMoa1813904

Article  PubMed  Google Scholar 

Lawson M, Cureton N, Ros S, Cheraghchi-Bashi-Astaneh A, Urosevic J, D’Arcy S, Delpuech O, DuPont M, Fisher DI, Gangl ET, Lewis H, Trueman D, Wali N, Williamson SC, Moss J, Montaudon E, Derrien H, Marangoni E, Miragaia RJ, Gagrica S, Morentin Gutierrez P, Moss T, Maglennon GA, Sutton D, Polanski R, Rosen A, Cairns J, Zhang P, Sánchez-Guixé M, Serra V, Critchlow SE, Scott JS, Lindemann JPO, Barry ST, Klinowska T, Morrow CJ, Carnevalli LS (2023) The next-generation oral selective estrogen receptor degrader camizestrant (AZD9833) suppresses ER+ breast cancer growth and overcomes endocrine and CDK4/6 inhibitor resistance. Cancer Res. https://doi.org/10.1158/0008-5472.CAN-23-0694

Article  PubMed  PubMed Central  Google Scholar 

Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377(6):523–533. https://doi.org/10.1056/NEJMoa1706450

Article  CAS  PubMed  Google Scholar 

Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roché H, Im YH, Eiermann W, Quek RGW, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, Ettl J (2020) Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol 31(11):1526–1535. https://doi.org/10.1016/j.annonc.2020.08.2098

Article  CAS  PubMed  Google Scholar 

Martin JM, Handorf EA, Montero AJ, Goldstein LJ (2022) Systemic therapies following progression on first-line CDK4/6-inhibitor treatment: analysis of real-world data. Oncologist 27(6):441–446. https://doi.org/10.1093/oncolo/oyac075

Article  PubMed  PubMed Central  Google Scholar 

Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G et al (2012) Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 30(22):2718–2724. https://doi.org/10.1200/JCO.2011.39.0708

Article  CAS  PubMed